High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review

Roisin Connolly, John A. McCaffrey

Research output: Contribution to journalArticle

Abstract

Context: High-dose chemotherapy (HDCT) with stem cell transplantation (SCT) has been investigated as a treatment strategy for advanced germ cell cancer (GCC) for >2 decades. In an effort to improve on the overall cure rates of 80% achievable with conventional chemotherapy, researchers have investigated this therapeutic option as a first-line therapy for those with poor-prognosis disease and as a salvage therapy for those with relapsed or refractory disease. Objective: The primary objective of this review is to define the role of HDCT plus SCT in advanced GCC. Prognostic indicators for this group of patients are also presented. Evidence acquisition: A Medline search of English-language literature was performed to identify studies published in the last 20 yr relating to the use of HDCT plus SCT in advanced GCC. Phase 1, phase 2, and phase 3 trials were included, as were retrospective reviews and meta-analyses. Evidence synthesis: Phase 2 trials investigating HDCT plus SCT as a therapeutic option for advanced germ cell cancer have indicated a survival advantage over conventional chemotherapy. This has not been confirmed in the phase 3 setting. Alternative chemotherapeutic strategies and options following failure of HDCT plus SCT are discussed. Conclusions: Studies to date have not indicated a survival advantage for the use of HDCT plus SCT in advanced germ cell cancer. Many questions, however, remain unanswered, and further research is required to identify whether optimising the strategy of HDCT plus SCT will improve outcome in this predominantly young group of patients.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalEuropean Urology
Volume56
Issue number1
DOIs
StatePublished - Jul 2009

Fingerprint

Germ Cell and Embryonal Neoplasms
Stem Cell Transplantation
Drug Therapy
Salvage Therapy
Survival
Therapeutics
Meta-Analysis
Language
Research Personnel

Keywords

  • Germ cell cancer
  • High-dose chemotherapy
  • Stem cell transplant
  • Testicular cancer

ASJC Scopus subject areas

  • Urology

Cite this

High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer : A Review. / Connolly, Roisin; McCaffrey, John A.

In: European Urology, Vol. 56, No. 1, 07.2009, p. 57-64.

Research output: Contribution to journalArticle

Connolly, Roisin ; McCaffrey, John A. / High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer : A Review. In: European Urology. 2009 ; Vol. 56, No. 1. pp. 57-64.
@article{01948f1e02db436e8d5a3c51ed3f22af,
title = "High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer: A Review",
abstract = "Context: High-dose chemotherapy (HDCT) with stem cell transplantation (SCT) has been investigated as a treatment strategy for advanced germ cell cancer (GCC) for >2 decades. In an effort to improve on the overall cure rates of 80{\%} achievable with conventional chemotherapy, researchers have investigated this therapeutic option as a first-line therapy for those with poor-prognosis disease and as a salvage therapy for those with relapsed or refractory disease. Objective: The primary objective of this review is to define the role of HDCT plus SCT in advanced GCC. Prognostic indicators for this group of patients are also presented. Evidence acquisition: A Medline search of English-language literature was performed to identify studies published in the last 20 yr relating to the use of HDCT plus SCT in advanced GCC. Phase 1, phase 2, and phase 3 trials were included, as were retrospective reviews and meta-analyses. Evidence synthesis: Phase 2 trials investigating HDCT plus SCT as a therapeutic option for advanced germ cell cancer have indicated a survival advantage over conventional chemotherapy. This has not been confirmed in the phase 3 setting. Alternative chemotherapeutic strategies and options following failure of HDCT plus SCT are discussed. Conclusions: Studies to date have not indicated a survival advantage for the use of HDCT plus SCT in advanced germ cell cancer. Many questions, however, remain unanswered, and further research is required to identify whether optimising the strategy of HDCT plus SCT will improve outcome in this predominantly young group of patients.",
keywords = "Germ cell cancer, High-dose chemotherapy, Stem cell transplant, Testicular cancer",
author = "Roisin Connolly and McCaffrey, {John A.}",
year = "2009",
month = "7",
doi = "10.1016/j.eururo.2009.03.018",
language = "English (US)",
volume = "56",
pages = "57--64",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - High-Dose Chemotherapy plus Stem Cell Transplantation in Advanced Germ Cell Cancer

T2 - A Review

AU - Connolly, Roisin

AU - McCaffrey, John A.

PY - 2009/7

Y1 - 2009/7

N2 - Context: High-dose chemotherapy (HDCT) with stem cell transplantation (SCT) has been investigated as a treatment strategy for advanced germ cell cancer (GCC) for >2 decades. In an effort to improve on the overall cure rates of 80% achievable with conventional chemotherapy, researchers have investigated this therapeutic option as a first-line therapy for those with poor-prognosis disease and as a salvage therapy for those with relapsed or refractory disease. Objective: The primary objective of this review is to define the role of HDCT plus SCT in advanced GCC. Prognostic indicators for this group of patients are also presented. Evidence acquisition: A Medline search of English-language literature was performed to identify studies published in the last 20 yr relating to the use of HDCT plus SCT in advanced GCC. Phase 1, phase 2, and phase 3 trials were included, as were retrospective reviews and meta-analyses. Evidence synthesis: Phase 2 trials investigating HDCT plus SCT as a therapeutic option for advanced germ cell cancer have indicated a survival advantage over conventional chemotherapy. This has not been confirmed in the phase 3 setting. Alternative chemotherapeutic strategies and options following failure of HDCT plus SCT are discussed. Conclusions: Studies to date have not indicated a survival advantage for the use of HDCT plus SCT in advanced germ cell cancer. Many questions, however, remain unanswered, and further research is required to identify whether optimising the strategy of HDCT plus SCT will improve outcome in this predominantly young group of patients.

AB - Context: High-dose chemotherapy (HDCT) with stem cell transplantation (SCT) has been investigated as a treatment strategy for advanced germ cell cancer (GCC) for >2 decades. In an effort to improve on the overall cure rates of 80% achievable with conventional chemotherapy, researchers have investigated this therapeutic option as a first-line therapy for those with poor-prognosis disease and as a salvage therapy for those with relapsed or refractory disease. Objective: The primary objective of this review is to define the role of HDCT plus SCT in advanced GCC. Prognostic indicators for this group of patients are also presented. Evidence acquisition: A Medline search of English-language literature was performed to identify studies published in the last 20 yr relating to the use of HDCT plus SCT in advanced GCC. Phase 1, phase 2, and phase 3 trials were included, as were retrospective reviews and meta-analyses. Evidence synthesis: Phase 2 trials investigating HDCT plus SCT as a therapeutic option for advanced germ cell cancer have indicated a survival advantage over conventional chemotherapy. This has not been confirmed in the phase 3 setting. Alternative chemotherapeutic strategies and options following failure of HDCT plus SCT are discussed. Conclusions: Studies to date have not indicated a survival advantage for the use of HDCT plus SCT in advanced germ cell cancer. Many questions, however, remain unanswered, and further research is required to identify whether optimising the strategy of HDCT plus SCT will improve outcome in this predominantly young group of patients.

KW - Germ cell cancer

KW - High-dose chemotherapy

KW - Stem cell transplant

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=67349171549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349171549&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2009.03.018

DO - 10.1016/j.eururo.2009.03.018

M3 - Article

C2 - 19303697

AN - SCOPUS:67349171549

VL - 56

SP - 57

EP - 64

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 1

ER -